目的 探究奧拉西坦治療腦梗死急性期的臨床療效。方法 選取2012年6月—2014年6月在天津市武清區(qū)人民醫(yī)院接受治療的腦梗死急性期患者200例, 隨機分為對照組和治療組, 每組100例。對照組采用常規(guī)方法治療, 治療組在對照組治療的基礎上靜脈滴注奧拉西坦注射液, 4 g/次加入到250 mL生理鹽水中。兩組均連續(xù)治療3周。治療后, 觀察兩組的臨床療效, 同時比較兩組治療前后血管損傷因子抗心磷脂抗體(ACA)、高敏C反應蛋白(hsCRP)、同型半胱氨酸(Hcy)、NIHSS評分、Barthel指數(shù)的變化。結(jié)果 治療后, 對照組和治療組總有效率分別為79.0%、96.0%, 兩組總有效率比較差異有統(tǒng)計學意義(P<0.05)。治療后, 兩組ACA、hsCRP、Hcy、NIHSS評分均較同組治療前顯著降低, Barthel指數(shù)顯著升高, 同組治療前后差異具有統(tǒng)計學意義(P<0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組, 兩組比較差異有統(tǒng)計學意義(P<0.05)。結(jié)論 奧拉西坦治療腦梗死急性期具有較好的臨床療效, 可降低神經(jīng)功能損傷和血管損傷因子的相關指標, 同時還可提高患者的Barthel指數(shù), 在臨床具有一定的推廣應用價值。

Objective To explore the efficacy of oxiracetam in treatment of cerebral infarction in acute phase. Methods Patients (200 cases) with cerebral infarction in acute phase in the People's Hospital of Wuqing from June 2012 to June 2014 were randomly divided into control and treatment groups, and each group had 100 cases. The patients in the control group were given conventional treatment. The patients in the treatment group were iv administered with Oxiracetam Injection, 4.0 g/time adding into physiological saline 250 mL. Two groups were treated for 3 weeks. After treatment, the efficacy was evaluated, and the changes of ACA, hsCRP, Hcy, NIHSS scores, and Barthel Index in two groups were compared. Results The efficacies in the control and treatment groups were 79.0% and 96.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, ACA, hsCRP, Hcy, and NIHSS scores were significantly reduced, and Barthel Index were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusions Oxiracetam has good clinical efficacy in treatment of cerebral infarction in acute phase, and can reduce nerve function damage and related indexes of blood vessel damage, while can improve Barthel Index, which has certain application value in clinical.